Treatment of bloodstream infections in ICUs by unknown
REVIEW Open Access
Treatment of bloodstream infections in ICUs
Jean-François Timsit1,2,3*, Jean-François Soubirou3, Guillaume Voiriot3, Sarah Chemam3, Mathilde Neuville3,
Bruno Mourvillier3, Romain Sonneville3, Eric Mariotte3, Lila Bouadma1,2,3 and Michel Wolff1,2,3
Abstract
Bloodstream infections (BSIs) are frequent in ICU and is a prognostic factor of severe sepsis. Community acquired
BSIs usually due to susceptible bacteria should be clearly differentiated from healthcare associated BSIs frequently
due to resistant hospital strains. Early adequate treatment is key and should use guidelines and direct examination of
samples performed from the infectious source. Previous antibiotic therapy knowledge, history of multi-drug resistant
organism (MDRO) carriage are other major determinants of first choice antimicrobials in heathcare-associated and
nosocomial BSIs. Initial antimicrobial dose should be adapted to pharmacokinetic knowledge. In general, a high dose
is recommended at the beginning of treatment.
If MDRO is suspected combination antibiotic therapy is mandatory because it increase the spectrum of treatment.
Most of time, combination should be pursued no more than 2 to 5 days.
Given the negative impact of useless antimicrobials, maximal effort should be done to decrease the antibiotic
selection pressure. De-escalation from a broad spectrum to a narrow spectrum antimicrobial decreases the antibiotic
selection pressure without negative impact on mortality. Duration of therapy should be shortened as often as possible
especially when organism is susceptible, when the infection source has been totally controlled.
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Introduction
Bloodstream infections (BSI) are a major cause of mor-
bidity and mortality worldwide [1]. These infections may
arise secondarily to localized infection at a specific body
site, or may be classified as primary when no focus is
identified. Severe sepsis, septic shock, and multisystem
organ dysfunction related to BSI frequently require ad-
mission in ICU for appropriate management [2]. BSI, as
a complication of critical illness, occurs in approximately
5% of all patients admitted to ICUs [3,4]. The case-
fatality rate associated with BSI reaches 35-50% when
associated with admission to ICU [1].
The mainstay of therapy for patients with bacteremia
remains antimicrobial therapy, together with the optimal
management of its consequences (e.g., shock or meta-
static suppurative complications), and surgical treatment
of an infection site (e.g., debridement, abscess drainage,
or removal of intravascular devices), when appropriate.
Considering the paucity of new antimicrobials in the
industry pipeline, and the emergence of strains resistant
to recent antimicrobials , enhanced efforts must be made
to decrease selection pressure to antimicrobials [5]. To
contain the worldwide problem of antimicrobial resist-
ance, intensivists have two major tools with regards to
antimicrobials treatments: [1] antimicrobial de-escalation,
and [2] shortened duration of antimicrobial therapy. Avail-
able data suggest that the treatment should be shortened
systematically [6] or based on the evolution of procalcito-
nin levels [7,8].
We will review the main elements that should be
taken into account for treating BSIs in ICU (figure).
At the initiation of antimicrobial therapy
Early appropriate antibiotic therapy is a fundamentally
important aspect of therapy of patients with BSI. Ad-
equate treatment requires [1] that all organisms isolated
from blood are susceptible in vitro to the antimicrobials
chosen; [2] a proper route and dose, and [3] an early ad-
ministration after blood cultures collection. In a recent
large hospital cohort study, Retamar et al showed that,
even fully adjusted on confounding factors, inadequate
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antibiotic therapy within 24 hours was associated with a
significant OR of 3 for the 14-day mortality and 1.70 for
the 30-day mortality, respectively [9]. In a large cohort
of septic patients, Kumar et al found that inadequate
therapy within 6 hours after onset of hypotension was
associated with an increase of the risk of death by more
than 5-fold in case of septic shock, and by more than
9-fold if a BSI is associated to the septic shock [10].
In a very recent analysis of the surviving sepsis cam-
paign dataset involving 17,990 patients with severe
sepsis who received appropriate antimicrobials, after a
careful adjustment on severity, geographic region, ad-
mission source, the mortality increased steadily by
about 1 percent per hour from 24.6% when treatment was
adequate within one hour to 33.1% when treatment was
adequate after the 6th hour [11]. In the Eurobact study
[12], an increased mortality was observed among patients
who had hospital-acquired bacteremia and were hospi-
talized in ICU but never appropriately treated (adjusted
odds ratio 1.56; 95% CI 1.04-2.35, p = 0.03). Conversely, a
very early treatment (<one day after having drawn the first
positive blood culture) was not associated with a de-
creased risk of death as compared to rather delayed ap-
propriate treatments (<2 days and < 5 days). Some kind
of underdosage, associated with the increase of the vol-
ume of distribution and the paradoxical increase in
glomerular filtration frequently observed in case of sep-
tic shock, may explain this result.
The initial antimicrobial therapy is necessarily empiric,
targeting the most likely etiologic pathogens. When risk
factors of antibiotic resistance are identified in patients
with a serious infection, broad spectrum antimicrobials
should be prescribed. The determinants of first-choice
molecules when empirical treatment is described in
Figure 1.
In a post hoc analysis among emergency department
patients undergoing a quantitative resuscitation protocol
for septic shock, Puskarich et al found that [13] the risk
of death increased when antimicrobials were delayed
until after the onset of shock (odds ratio = 2.59 95% CI
1.17-5.78). This suggests that, if an aggressive resuscita-
tion is performed early, the timing of initial antibiotic
therapy may have lesser importance.
On the opposite, when antimicrobial are started in
the first hours of severe sepsis, the recent Protocolized
Care for Early Septic Shock (ProCESS) trial have found
no difference in mortality between an aggressive ther-
apy of organ hypoperfusion that require the place-
ment of a central venous catheter, administration of
inotropes, or blood transfusions, a protocol-based
standard therapy that did not, or an up-to-date usual
care [14].
While controversy exists regarding which elements
of sepsis resuscitation bundles are most beneficial, it
is intuitive that good principles of care dictate that
appropriate antimicrobials be prescribed promptly in
the setting of severe infection.
Epidemiology of resistant bacteria
Epidemiological data about spread of MDRO has been
updated by the WHO organization very recently. These
data clearly found a global increase in the risk of
bacterial resistance mainly gram negative bacteria
with great variability between countries. The global
report updated in april 2014, is available in the WHO
website (http://www.who.int/drugresistance/documents/
surveillancereport/en/; accessed august 22nd 2014). These
general data collected mainly by hospital lab imperfectly
reflect the pathogen responsible for bacteremia in ICU
patients.
For community-acquired infections, recovered micro-
organisms are mainly Streptococcus pneumoniae and
Staphylococcus aureus for Gram positive, and Escherichia
coli for Gram negative. The betalactams active against
these bacterias did not change in the past decade. How-
ever, extended spectrum beta-lactamase (ESBL)-producing
E. coli and community acquired MRSA are more and more
reported.
The fecal carriage of ESBL E. coli (mainly CTX M-15),
which was unknown before the turn of the millennium,
has since increased significantly everywhere, with devel-
oping countries being the most affected (Southeast
Asia, Eastern Mediterranean region, Western Pacific
region). Intercontinental travels may have emphasized
and globalized the issue [15]. Among European sub-
jects with traveler’s diarrhea, returning from diverse
overseas areas, ESBL-E. coli carriage rates were ob-
served in 1 out of five. These rates increased signifi-
cantly after travel to Egypt, India, Southeast Asia,
Thailand, and the Middle East [16]. In a prospective
case-control study performed in 2008, European trav-
elers had a 23% ESBL-E. coli carriage rate, which was
significantly more than the 4% found in non travelers.
Upon return from India, Africa, or Asia, the ESBL-E
carriage rate reached 46% [17]. The duration of carriage
after travel seems to be relatively short, lasting only
a few weeks. The practical consequences of these
epidemiological changes is that empirical therapy of
septic shock probably due to Gram negative organisms
(i.e., urinary tract infections or intra-abdominal infections)
after returning from endemic areas must cover ESBL
Enterobacteriaceae.
Community-acquired methicillin-resistant S. aureus
(CA-MRSA) is another matter of concern. CA-MRSA
responsible of community acquired pneumonia (CAP) is
very uncommon in Europe [18] (less than 1% of CAP)
but much more frequent (8-10%) in USA. MRSA treat-
ment in case of CAP is not recommended [19], but
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should be borne in mind in case of severe necrotizing
CAP with hemoptysis and leucopenia, often preceded by
influenza infection [20].
For nosocomial and health-care associated (HCA)
bloodstream infections, resistance profile is highly
dependent on national and local epidemiology. Hospital-
acquired and HCA BSIs are associated with increased inci-
dence of multi-resistant drug microorganisms (MDRO),
such as MRSA, ESBL producing Enterobacteriaceae, Acine-
tobacter baumannii, and Pseudomonas aeruginosa. In
these cases, it is more difficult for empiric treatment to be
appropriate, especially in patients admitted in the ICU with
a major incidence of multidrug-resistant microorganisms
[21,22]. In these cases, in addition to applying guidelines
recommendations, it is indispensable to know the local
flora predominant in each area before initiating empiric
antibiotic treatment.
Table 1 displays the distribution of organisms from
recent studies investigating the epidemiology of BSIs
in ICUs. The most important change in the epidemi-
ology of ICU-related BSI in recent years is the emer-
gence of highly resistant organisms, particularly extensively
Figure 1 Decision tree including main determinants guiding the choice of the most appropriate antimicrobial therapy. (BSI: bloodstream
infection; MDRO: multiresistant drug organism; TDM: therapeutic drug monitoring; MIC: minimum inhibitory concentration).
Timsit et al. BMC Infectious Diseases 2014, 14:489 Page 3 of 11
http://www.biomedcentral.com/1471-2334/14/489
Table 1 Microorganisms recovered from BSIs in ICU in the main recent studies
Author Marra 2011[23] Prowle 2011 [4] Valles 2011 [24] Corona 2010 [25] Tabah 2012 [12]
(countries) (Brazil) (Australia) (Spain, Argentina) (Europe, Australasia, South America, Asia) (Europe, South America, China, Canada)
Type of BSI (number of cases) HAB (1196) ICU-AB (330) CAB (343) HCAB (131) HAB (252) CAB (431) HAB (351) ICU-AB (915) HAB (279) ICU-AB (877) % MDROb
S. pneumoniae 21.4% 10.9% 1.4% 0.4% – –
S. aureus 12.8% 26.7% 10.3%a 13.8%a 9.6%a 22.3% 26.2% 23.6% 16.1% 8.4% 60%
CoNS 16.6% 24.3% 3.5% 6.2% 10.8% 16.5% 19.7% 29.6% 10% 12.7% –
Enterococcus spp. 5.5% 17% 1.5% 4.6% 8.4% 7.2% 9.1% 11.4% 10% 12.9% 43.5%
E. coli Gram negative 28.2% 20.5% 26.9 18.5% 19% 9.7% 5.6% 19% 5.1% 66.7%
Enterobacter spp. 5.8% 2.3% 6.9% 3.6% 2.6% 4.8% 6.3% 7.2% 7.6% 50%
Klebsiella spp. 11.8% 4.1% 4.6% 6.0% 4.6% 8.6% 8.5% 8.2% 15.2% 90.9%
Serratia spp. 3.2% 1.8% 2.6% 69%
Proteus spp. 1.8% 3.3% 1.4% 1.5% 1.4% 1.7% 20%
P. aeruginosa 10% 1.8% 4.6% 6.4% 6% 10.3% 9.7% 10.4% 12.5% 60%
Acinetobacter spp. 11.8% 0.9% 5.4% 5.7% 7.5% 15.7% 95.2%
Anaerobes 3.2% 1.5% 1.6% 3.9% 0.7% 0
Candida spp. 5.8% 15.5% 1.5% 3.8% 8.4% 4.9% 10.5% 6.5% 7.5% 8.2% –
Legend: HAB: hospital-acquired BSI, ICU-AB: ICU acquired BSI, HCAB: healthcare-associated BSI, MDRO : multi drug resistant organisms.
a: MRSA represents 3% of CAB, 27.5% of HCAB and 54.1% of HAB.




















resistant Gram negative bacteria including P. aeruginosa,
A. baumannii and Klebsiella pneumoniae [26-28].
Timing of BSI onset versus hospital admission
BSIs are generally classified as either being community-
acquired (CA) or nosocomial infections [29]. However,
moe and more patients with complex medical problems
are now managed in the community setting. Those pa-
tients managed in the outpatient setting have infections
that share many clinical, microbiologic, and outcome
characteristics with nosocomial infections. As a result, a
new category of healthcare-associated (HCA) community-
onset infections has become widely recognized [30].
Traditional risk factors of HCA infections are [1] resi-
dency in a nursing home or long-term care facility in the
30 days before the BSI. [2] hospitalization in an acute
care hospital for 48 h or longer in the 90 days before the
BSI. [3]. Attended a hospital or dialysis clinic or received
intravenous chemotherapy in the 30 days before the BSI.
[4] Received intravenous therapy, wound care, enteric
nutrition, or specialized nursing care at home, in the
30 days before the BSI but the respective impact of each
risk factor has never been fully investigated and probably
vary between countries [31].
In hospital settings, many recent publications showed
that S.aureus, P aeruginosa is much more common in
HCA-BSI than in CA BSI. E coli is more frequent in CA
BSI but the rate of ESBL E coli is similar between CA
and HCA BSIs [31-37]. To the best of our knowledge
there is no study that has compared microorganisms re-
sponsible from HCA-BSI and CA or HA BSI admitted
in ICUs.
Patient’s prior antimicrobial history
If a prior antibiotic use is known, it should be consid-
ered in conjunction with previous bacterial culture and
antimicrobial susceptibility testings, for setting up an ap-
propriate treatment [38]. Most of the time, the prior use
of one antibiotic is associated with an increase in the
risk of infection with a microorganism resistant to it
[39,40]. In area where the rate of carbapenem-resistant
micro-organism is important, previous antimicrobial
therapy is of key importance. The duration of exposure
to carbapenems (OR 1.079 per day of exposure, 95% CI
1.022-1.139, p = 0.006) and to colistin (OR 1.113 per
day of exposure, 95% CI 1.046-1.184, p = 0.001) were
independent risk factors for acquisition of CR-GNB
bacteremia in a Greek ICU [41]. Indeed, previous anti-
microbial therapy strongly modified the gut microbiota,
the main reservoir of potential pathogens in ICU patients.
As an example, in our ICU, Armand-Lefevre and col-
leagues [42] found that imipenem resistant Gram negative
bacteria (IRGNB) in the digestive flora increased regularly
from 5.6% after 1 week to 58.6% after 6 weeks in the ICU.
Imipenem exposure was the main risk factor of IRGNB.
As compared to patients that did not received imipenem,
the odds ratio for colonization was already as high as 5.9
(95% confidence interval [43], 1.5 to 25.7) after only 1 to
3 days of exposure and increased up to 7.8 (95% CI, 2.4
to 29.8) thereafter.
Source of infection
The source of infection is another key element to choose
empirical therapy with two objectives. We need to adapt
the choice of antimicrobials to the probable agents re-
sponsible for infection and to the diffusion of antimicro-
bials to infected tissues.
For CA infections, pneumonia is associated with
bacteremia in 15% cases. S. pneumoniae represents the
main cause of bacteremia of respiratory origin, followed
by S. aureus, as showed by a recent large multicenter
ICU cohort study [44]. Enterobacteriaceae and P. aerugi-
nosa are encountered in less than 5% of the CA pneu-
monia, mainly HCA-pneumonia, but is associated with
bacteremia in about half of the cases [45]. For digestive
and urinary tract infection, E. coli is by far the main cause
of CA BSI.
In the French national network REA RAISIN in 2013
(213 ICUs, 34 278 patients), the main causes of ICU-
acquired bacteremia were intravascular catheters (29.2%),
lower respiratory tract infections (18.0%) and digestive
tract (13.6%). The source of ICU-acquired bacteremia
remained unknown in 24.9% cases. In the same network,
the main causes of catheter-related BSIs were coagulase
negative staphylococci (28%), S. aureus (23%), P. aerugi-
nosa (12%), E. coli (8%) and multiple causes (11.5%) [46].
In a post hoc analysis of the Eurobact study among
230 patients with HA-BSI respiratory infections (HABSI
requiring ICU admission, n = 40; ICU-acquired, nonin-
vasively ventilated respiratory BSI, n = 30; and ICU-
acquired, invasively ventilated BSI, n = 160) were compared
to 749 patients with HA-BSI not related to respiratory
infections. HA-BSI respiratory infections were more
frequently due to Gram negative pathogens (76.3% vs.
56.7%, P < 0.0001), mainly A. baumannii (18.3% vs. 10.4%,
P = 0.0007), Klebsiella spp. (18.7% vs. 11%, P = 0.0013),
and were less frequently due to Gram-positive cocci (23.3%
vs. 41.2%, P < 0.0001), with the exception of S. aureus
(11.3% vs. 9.5%, P = 0.39). HA-BSI respiratory infections
were more frequently associated with MDRO (53.9% vs.
42.7%, P = 0.0003) [47].
In a retrospective single-center analysis of 96 patients
who developed BSI of abdominal origin admitted in
ICU, de Waele et al showed that secondary peritonitis,
intra-abdominal abscesses and cholangitis were the
sources of the BSI in the majority of patients. Gram-
negative, especially E. coli, were frequently recovered.
BSI was polymicrobial in 22% of the cases [48]. Based on
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epidemiological data and guidelines, Table 2 proposed em-
pirical antibiotic therapy according to situations.
Mono- or bi-antimicrobial therapy?
Although combination therapy has been controversial in
regard to a synergistic effect, it is becoming increasingly
important to achieve adequate empirical therapy. Ami-
noglycoside use is associated with an increased risk
of impaired renal function; more generally, the use of
combination of antimicrobial exposed to more iatro-
genic and allergic complications than a single drug. The
impact of combination therapy as compared to mono-
therapy in resistant bacteria selection from the gut flora
is also debated. Theoretically, and in experimental stud-
ies, combination therapy exposes the gut microbiota to a
highest antibiotic selection pressure than monotherapy.
However, in a randomized trial among ICU patients
with severe sepsis, a combination of meropenem and
Table 2 Suggested empirical antimicrobial treatment of bloodstream infections according to source of infection and
place of acquisition (adapted from international guidelines and local pratice) [49-55]
Site Pathogens Suggested empirical antibiotic
Urinary tract infection Enterobacteriacae including - Ceftriaxone for CAB or ceftazidime for HAB or ICU AB
(if suspicion of P. aeruginosa)
- Escherichia coli ± aminoglycosides
Other enterobacteiraceae NB: Consider the risk of ESBL and administer a penem in
case of hish risk (CA and recent travel to high risk countries,
other situations in case of previous colonization, invasive





Intra-abdominal sepsis Gram negative bacilli including - Piperacillin-tazobactam
- Escherichia coli (all BSIs) - Cephalosporin active against P. aeruginosa +
metronidazole
- other enterobacteriaceae (all BSIs) - Carbapenem (high-risk patients)
- Pseudomonas aeruginosa (HA and ± fluconazole
ICU BSI) ± aminoglycoside




CA and HCA pneumonia S pneumoniae (CA BSI) - Third generation cephalosporin (macrolides in case
of suspicion of intracellular bacteria will be added
initially).S aureus (HCA BSI)
E coli (HCA BSI) - NB: In case of HCA, consider the risk of MRSA or ESBL
E coli.
Hospital acquired pneumonia Enterobacteriacae - Beta-lactam active against P. aeruginosa ±
aminoglycoside ± glycopeptide or linezolid if suspicion




Ventilator-associated pneumonia (no risk
factor for multi-drug resistant pathogen)
Staphylococcus aureus - Third generation cephalosporins
Streptococcus pneumoniae ± aminoglycosides or fluoroquinolones
Haemophilus influenzae
Anaerobes
Catheter-related infection Staphylococcus sp. - Glycopeptide or linezolid + beta-lactam active against
Pseudomonas aeruginosa
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moxifloxacin was associated to less emergence of re-
sistance at the infection site to meropenem and aminogly-
cosides than meropenem alone [56]. Underdosage of
antimicrobials and poor pharmacodynamic are certainly
the main risk factors for bacterial resistance emergence
among Gram negative microbiota.
In a retrospective propensity matched study, in case of
septic shock, Kumar et al found a 23% reduction in the risk
of death with the use of immediately adequate combination
therapy as compared to immediately adequate monother-
apy [57]. But in a cohort of 593 ICU patients with P aerugi-
nosa, BSI, there was no demonstrated benefit of a
combination therapy if the monotherapy is adequate
[58]. In a cohort of 760 patients with severe sepsis or
shock, inappropriate initial therapy increased the risk of
death (adjusted OR: 2.3); combination therapy decreased
the rate of inappropriate therapy from 36% to 22.2% [59].
The appropriate combination is also debated. The
benefit of combination with aminoglycosides has not
been found in the study by Kumar et al. [57]. On an-
other cohort of Gram negative bacteremia, combination
with aminoglycosides improved the appropriateness of
antimicrobial therapy in episodes due to ESBL or AmpC
producing Enterobacteriaceae and to P. aeruginosa. Com-
bination with aminoglycosides also improve prognosis of
patients with neutropenia and septic shock [60].
Right dosage
Prescription of an antibiotic for which the micro-
organism is supposed to be susceptible in vitro is not
synonymous of efficacy. It is especially the case for the
most severe patients (with increase in the volume of distri-
bution of antimicrobials) and for the less susceptible bugs,
for which available antimicrobials have MICs at the border
of susceptibility breakpoints.
Pharmacokinetic/pharmacodynamic (PK/PD) targets
need to be achieved for decreasing the risk of treatment
failure and selection of resistant pathogens [61].
The main pharmacodynamic properties that correlate
with efficacy for largely used antimicrobials are the time
above the MIC for beta-lactams and carbapenems, the
ratio maximal concentration/MIC (Cmax/MIC) for fluor-
oquinolones, aminoglycosides, daptomycin, and colistin,
and the area under the curve above the MIC (AUIC) for
glycopeptides.
Estrely et al [62] studied the impact of MICs to
carbapenems of multiresistant Gram negative bacteria
(P. aeruginosa, A. baumannii and Beta-lactamases produ-
cer Enterobacteriaceae) on the outcome of 71 patients with
BSIs. Overall, 52 patients survived, and 19 died. This study
revealed that patients with organisms that had a MIC
of > 4 mg/L had worse outcomes than patients whose iso-
lates had a MIC of <2 mg/L, even after adjustment for con-
founding variables (16.1% versus 76.9%; P < 0.01). Indeed,
it has been demonstrated that beta-lactams used in critic-
ally ill infected patients achieved infrequently their phar-
macodynamic target. Usual targets for beta lactams are
free antibiotic concentration above the MIC (fT >MIC) of
the pathogen at both 50% and 100% of the dosing interval.
In the recent DALI study, involving 248 patients with in-
fection, 16% of the beta-lactam administration did not
achieve the 50% target and 32% did not achieve the 100%
target. Importantly, a positive clinical outcome was associ-
ated with 50% and 100% fT >MIC (OR = 1.02 and 1.56,
p < 0.03) [63]. In practice, we should know the MIC50
and MIC90 of the suspected pathogens, and ask for
specific MICs after pathogen identification, especially for
MDRO and extensively resistant pathogens.
For hydrophilic antibiotics such as beta-lactams, ami-
noglycosides, glycopeptides or colistin, the increase in
the volume of distribution observed in severe patients
leads to a decrease of the antibiotic concentrations. Fur-
thermore, in young people without immediate renal
dysfunction, a paradoxical increase in the glomerular
filtration is observed. Both mechanisms argue for the
administration of an important initial dose of antimi-
crobials (loading dose), in order to reach pharmacody-
namic targets at the initiation of treatment (suggested
initial doses are in Table 3). For lipophylic antibiotics such
as fluoroquinolones, the volume of distribution is grossly
unchanged and clearance depends on hepatic function.
Table 3 Suggested intravenous of initial selected
antibiotic doses in critically ill patients during the first
24 hours of treatment of bacteremia with severe sepsis in
ICU (to be adapted in case of kidney injury and renal
replacement therapy) (adapted from [61,63-66]
Antibiotic class
Aminoglycosides Amikacin 25 mg/kg
Gentamicin 7 mg/kg
Interval administration and doses adjusted
according to TDM
Fluoroquinolones Ciprofloxacin 400 8 hourly
Colistin 9-12 MU (720-960 mg) loading dose followed by
480 mg 12 hourly if patient without kidney injury.
Beta-lactams Cefepime 2 g 8 hourly
Ceftazidime 2 g 6 hourly
Imipenem 1 g 6-8 hourly
Meropenem 1 g 6-8 hourly
Ertapenem 1 g 12 hourly
Piperacillin-Tazobactam 4.5 g 6 hourly
Glycopeptides Vancomycin 35 mg/kg in a 1 hour infusion loading
dose followed by 30 mg/kg continuous infusion
Daptomycin 8-12 mg/kg 24 hourly
Tigecyclin 200 mg followed by 100 mg 12 hourly when
borderline susceptibility is suspected
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For time-dependent antimicrobials such as beta lac-
tams or glycopeptides, the use of continuous or ex-
tended infusions of antimicrobial is able to increase the
fT >MIC. Continuous infusion required the antimicrobial
to be stable after preparation at room air temperature.
It has been tested successfully with ceftazidime, cefe-
pime, piperacillin-tazobactam, doripenem, meropenem
and vancomycin. The clinical proof of superiority of
extended or continuous infusion of betalactams or vanco-
mycin is suggested by few studies [64,67-71], and required
further trials.
For concentration dependent antimicrobials, such as
aminoglycosides [72,73] or colistin [65,66], the use of
increased doses increased the probability to reach the
pharmacodynamic targets.
Therapeutic drug monitoring (TDM) is common place,
given uncertainties on the antimicrobial concentration
actually achieved, especially for aminoglycosides and gly-
copeptides. Recent data have also shown that TDM of
beta-lactams leads to dose adjustment in about half of
cases [63,74].
In case of kidney injury, hydrophylic antibiotics clear-
ance will be largely modified. Intensity of continuous
renal replacement therapy and degree of residual renal
function are crucial factors in accurately determining the
antimicrobial requirement.
Right after the initiation of the antimicrobial therapy
Results of microbiological exams
Despite all previous knowledge, antibiotic therapy
remained initially inadequate in 20-40% of the cases, even
if broad spectrum combination therapy is used. Micro-
biological samples, collected just before antimicrobial
start, may help to document the infection and decrease
the risk of inadequate treatment. Good collaboration
with the microbiological laboratory, Gram stain examin-
ation and new molecular techniques able to detect early
various antimicrobial resistance mechanisms are im-
portant strategies to be developed in order to shorten
the delay for appropriate treatment and subsequent de-
escalation [75-78].
Source control
Source control is recognized as an important part of the
treatment of BSIs and has been recently shown to be in-
dependently related with outcome [12,79]. The source
control should be optimal, especially when microorgan-
isms are less susceptible to antimicrobials or when anti-
microbial diffusion is hazardous.
During the antimicrobial therapy
De-escalation
Antimicrobial de-escalation is a clinical approach to em-
pirical antibiotic treatment of bacteremia that attempts
to balance the need for appropriate initial therapy with
the need to limit unnecessary antimicrobial exposure, in
order to curtail the emergence of resistance.
Paradoxically, although de-escalation is associated with
no or a positive impact on mortality [80], its impact on
overall antibiotic consumption has not been clearly dem-
onstrated. It has even been associated with an increase
in the number of days on antibiotics [81]. However, it
clearly reduced the broad-spectrum antibiotic use. The
value of such streamlining may seem intuitive to infec-
tious diseases physicians, but for many other physicians,
an attitude of “don’t change a winning team” is perva-
sive. The persistently reported figures of around 50%
de-escalation delivery are unacceptable and must be
improved. The requirement for multiple antimicrobials
to achieve adequate initial therapy further emphasizes
the need for obtaining both timely blood culture and
early culture results through incorporation of molecu-
lar diagnostics for bacteremia [78,82] so that subse-
quent antimicrobial de-escalation can be performed in a
rational manner [82].
Length of antimicrobial therapy
Up to half of the antibiotic use is unnecessary or in-
appropriate, and excessive duration is the greatest con-
tributor to inappropriate use. A reduction in the length
of antibiotic courses in ICU is an important strategy
to minimize the consequences of antimicrobial over-
use, including antibiotic resistance, Clostridium Difficile-
associated diarrhea, adverse effects and costs. Usual
length of therapy is about 10 days in routine, longer for
S. aureus bacteremia and shorter for coagulase-negative
staphylococci bacteremia [83].
Although large RCTs are missing, a meta-analysis of
available data suggested that a short (5-7 days) therapy,
vs. a longer one (7-21 days), is safe with respect to clin-
ical or microbiologic cure and survival [6]. Of note, ami-
noglycosides treatment should be limited to 2-5 days to
optimize efficacy and to limit potential toxicity.
Table 4 Arguments pro and against a short duration of
antibiotic therapy
Arguments for a short
treatment
Arguments for a longer
treatment
No comorbid conditions Immune depression
Source control No source control
Low MICs, high bactericidal titers MDR , XDR bacterias
Initial appropriate therapy Low bactericidal titers
Easy PK and tissue diffusion Poor PK and tissue diffusion
Source control appropriate Foreign materials
No foreign material Slow, partial clinical response
Rapid clinical improvement
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Of course, at the bedside, many factors should be
taken into account to decide to shorten the duration of
treatment (Table 4). A short duration of treatment
should be more cautiously decided when the initial treat-
ment was inadequate [84], when the therapeutic index
was low, when the source control was not optimal. In
immunocompromised patients, and when invasive de-
vices or foreign material are left in place, a longer treat-
ment is often recommended.
To reduce the duration of treatment, strategy should
also be guided by the evolution of patients’ status under
treatment and by biomarkers [85]. Procalcitonin (PCT)
serum level has been used in randomized control trial to
reduce the duration of therapy in severe infections. A
PCT-driven approach was responsible for an increase of
3.5 of the number of days alive without antibiotics at day
28, with no adverse impact, as compared to the standard
of care. Surprisingly, the PCT rules are not followed by
clinicians in about half of the cases, although it suggests
that regular monitoring of PCT may serve as a target to
propose stopping antimicrobials.
The use of external rules of therapy, of systematic
intervention of the antibiotic team of the hospital [86,87]
or bundles [88], simple educational programs with audit,
are also effective in reducing the antimicrobial consump-
tion to a similar extent without adverse events.
Finally individual patient therapy needs to be coupled
with adherence to optimal prevention practice to pre-
vent spread of resistant bacteria from patient to patient.
Conclusions
Bacteremia is an independent risk factor of mortality in
case of severe sepsis in ICU. Early adequate treatment of
bloodstream infections is required and is based on previ-
ous knowledge and guidelines, rapid microbiological
identification, adequate source control and adminis-
tration of proper antimicrobials at the adequate dose
regimen for the individual patient. These goals become
difficult to achieve in case of BSI due to multi-drug resist-
ant pathogens with high MICs to antimicrobials, in the
most severe patients where low antibiotic concentrations
are common, and when the source control is incomplete
or impossible. In these situations, pharmacodynamic
optimization and therapeutic drug monitoring should
be recommended.
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